The EDP-305 phase-2b outlay will be less if ENTA halts the study following the interim analysis; even so, if it were up to me I wouldn’t run this trial. I’m not convinced that data from the phase-2b interim analysis will materially help in the EDP-297 program, as someone suggested on Twitter.
News 
Market Data 
Discover 
